In vivo anti-tumor efficacy studies demonstrate a higher tumor inhibition rate of 45.1% for paclitaxel–transferrin formulation compared to 28.8% for paclitaxel nanosuspension treatment alone, and paclitaxel–transferrin formulation showed a lower level of toxicity. Here, TF is linked to neoplasm.